Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer?

1

Introduction

00:00 • 5min

2

HER2 Mutant - Is There a Receptor on the Cell Surface?

05:02 • 3min

3

The TDM One Trial in Lung Cancer

08:00 • 3min

4

HER2 Mutation in Non-Small Cell Lung Cancer

10:46 • 2min

5

Amplification in Lung Cancer

12:19 • 5min

6

Is Her-to Mutant Reacting to Immune Checkpoint Inhibitors?

16:59 • 2min

7

PD-1 Levels - Is Her One Really EJFR?

19:00 • 5min

8

HER3 Antibody Drug Conjugate

23:41 • 3min

9

Trastuzumab in Breast Cancer

26:39 • 2min

10

Trastuzumab and Lung Cancer

28:28 • 5min

11

TDM1 - Is There a Signal?

33:55 • 3min

12

TDXD - A New Antibody Drug Conjugate Compared to TDM1

36:27 • 5min

13

Drug Development Pathways for ADCs

41:50 • 4min

14

Is TDXD in Lung Cancer?

45:20 • 3min

15

TDXD and HER2 Mutant Lung Cancer - What Are the Side Effects?

48:27 • 5min

16

TDXD - Is Pembrochemo OK?

53:42 • 1min

17

Is There a Trial Design for Non-Small Cell Lung Cancer?

55:00 • 5min

18

Clinical Trials in Community Practices, You Know?

59:40 • 2min

19

Breast Cancer - Is Clistemab a Second Line Therapy?

01:01:13 • 2min

20

Lung Cancer Trials - ILD

01:03:19 • 4min

21

ILD in Lung Cancer?

01:07:26 • 3min

22

Breast Cancer - Is TDXD an Absolute Contraindication?

01:10:23 • 3min

23

Lung Cancer - Is There a Pan Tumor Approval for TDXDA?

01:13:07 • 3min

24

Breast Cancer

01:16:18 • 2min

25

Oncology Today - Dr. Neil Love for Oncology Today

01:18:01 • 2min